Bortezomib (PS-341)

Catalog No.S1013 Synonyms: LDP-341, MLM341

Molecular Weight(MW): 384.24

Bortezomib (PS-341) is a potent 20S proteasome inhibitor with K_i of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.

Cited by 190 Publications

Science, 2019, 363(6429)

PubMed: 30792274 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Cell, 2019, 35(1):46-63

PubMed: 30581152 ( click the link to review the publication )

Nature, 2018, 560(7718):325-330

PubMed: 30089904 ( click the link to review the publication )

Nature, 2017, 550(7677):534-538

PubMed: 29045385 ( click the link to review the publication )

Science, 2017, eaal3755

PubMed: 28302793 ( click the link to review the publication )

Science, 2017, eaal3755

PubMed: 28302793 ( click the link to review the publication )

Cell, 2017, 171(5):1094-1109

PubMed: 29149604 ( click the link to review the publication )

Nat Med, 2014, 20(6):599-606

PubMed: 24813251 ( click the link to review the publication )

Cell Stem Cell, 2012, 11(2):242-52

PubMed: 22862949 ( click the link to review the publication )

Nature, 2019, 567(7747):262-266

PubMed: 30842662 ( click the link to review the publication )

Nat Commun, 2019, 10(1):273

PubMed: 30655516 ( click the link to review the publication )

Leukemia, 2019, 33(1):171-180

PubMed: 30026574 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):28

PubMed: 30717817 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472

PubMed: 31142515 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(7):1205-1216

PubMed: 31092565 ( click the link to review the publication )

Hum Mutat, 2019, 40(4):392-403

PubMed: 30609140 ( click the link to review the publication )

Mol Oncol, 2019, 13(2):290-306

PubMed: 30422399 ( click the link to review the publication )

Mol Neurobiol, 2019, 56(3):1653-1664

PubMed: 29916141 ( click the link to review the publication )

Neoplasia, 2019, 21(7):653-664

PubMed: 31132676 ( click the link to review the publication )

Oxid Med Cell Longev, 2019, 2019:1659468

PubMed: 31281566 ( click the link to review the publication )

Biochim Biophys Acta Mol Cell Res, 2019, 1866(2):252-263

PubMed: 30445147 ( click the link to review the publication )

Mol Cancer Res, 2019, 10.1158/1541-7786.MCR-18-1332

PubMed: 31043489 ( click the link to review the publication )

ACS Chem Biol, 2019, 10.1021/acschembio-00191

PubMed: 31243962 ( click the link to review the publication )
Arthritis Res Ther, 2019, 21(1):50

PubMed: 30728075 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(3)

PubMed: 30736330 ( click the link to review the publication )

Apoptosis, 2019, 24(1-2):184-197

PubMed: 30498998 ( click the link to review the publication )

Biochimie, 2019, 162:46-54

PubMed: 30946948 ( click the link to review the publication )

Leuk Lymphoma, 2019, 10.1080/10428194.2019.1616190

PubMed: 31111763 ( click the link to review the publication )

Leuk Res, 2019, 78:12-20

PubMed: 30660961 ( click the link to review the publication )

Naunyn Schmiedebergs Arch Pharmacol, 2019, 392(4):461-466

PubMed: 30554340 ( click the link to review the publication )

J Blood Med, 2019, 10:105-109

PubMed: 31043801 ( click the link to review the publication )

J Clin Invest, 2018, 128(7):2877-2893

PubMed: 29863498 ( click the link to review the publication )

Leukemia, 2018, 32(1):139-148

PubMed: 28663576 ( click the link to review the publication )

Blood Cancer J, 2018, 8(11):105

PubMed: 30409995 ( click the link to review the publication )

ACS Appl Mater Interfaces, 2018, 10(26):21825-21835

PubMed: 29897225 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):29

PubMed: 29482577 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(7):1416-1429

PubMed: 29703842 ( click the link to review the publication )

Lab Invest, 2018, 98(6):708-714

PubMed: 29540860 ( click the link to review the publication )

Int Immunopharmacol, 2018, 54:39-45

PubMed: 29100036 ( click the link to review the publication )

Mol Cells, 2018, 41(12):1008-1015

PubMed: 30396235 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 505(1):126-133

PubMed: 30236985 ( click the link to review the publication )

Ann Diagn Pathol, 2018, 32:28-34

PubMed: 29414394 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(4):1012-1024

PubMed: 28151717 ( click the link to review the publication )

Cell, 2017, 170(5):860-874

PubMed: 28803730 ( click the link to review the publication )

Cell, 2017, 169(6):1105-1118

PubMed: 28575672 ( click the link to review the publication )

Sci Rep, 2017, 7(1):682

PubMed: 28386133 ( click the link to review the publication )

Hepatology, 2016, 64(1):161-74

PubMed: 26926206 ( click the link to review the publication )
Leukemia, 2016, 30(4):861-72

PubMed: 26658839 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-1462

PubMed: 25748087 ( click the link to review the publication )

Leukemia, 2015, 29(6):1390-401

PubMed: 25533804 ( click the link to review the publication )

Cancer Res, 2015, 10.1158/0008-5472.CAN-14-2109

PubMed: 25712341 ( click the link to review the publication )

Blood Cancer J, 2015, 5:e312

PubMed: 25978432 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2014.455

PubMed: 25619841 ( click the link to review the publication )

Cancer Lett, 2015, 10.1016/j.canlet.2015.02.044

PubMed: 25737303 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(2):223-30

PubMed: ( click the link to review the publication )

Traffic, 2015, 10.1111/tra.12287

PubMed: 25824657 ( click the link to review the publication )

J Virol, 2015, 89(5):2643-58

PubMed: ( click the link to review the publication )

Toxicol Sci, 2015, 10.1093/toxsci/kfv056

PubMed: 25766884 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(2):639-650

PubMed: ( click the link to review the publication )

Toxicol Appl Pharmacol, 2015, 283(1):1-8

PubMed: 25576094 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2015, 10.1016/j.taap.2015.03.018

PubMed: 25817892 ( click the link to review the publication )

Int J Oncol, 2015, 46(2):474-86

PubMed: ( click the link to review the publication )

Malar J, 2015, 14(1):200

PubMed: 25968882 ( click the link to review the publication )

J Bio Mater Res, 2015, 103(4):1476-84

PubMed: ( click the link to review the publication )

Chem Biol, 2015, 10.1016/j.chembiol.2015.01.004

PubMed: 25728267 ( click the link to review the publication )

Oncotarget, 2015, 51: S659-S660

PubMed: ( click the link to review the publication )

Sci Transl Med, 2014, 6(250):250ra112

PubMed: 25143362 ( click the link to review the publication )

Blood, 2014, 123(26):4120-31

PubMed: 24711662 ( click the link to review the publication )

J Clin Invest, 2014, 124(9):3757-66

PubMed: 25061876 ( click the link to review the publication )

Nat Commun, 2014, 5:3384

PubMed: 24594970 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(6):1576-89

PubMed: 24634471 ( click the link to review the publication )
Proc Natl Acad Sci USA, 2014, 111(16):E1591-9

PubMed: 24715725 ( click the link to review the publication )

Cancer Res, 2014, 74(16):4458-69

PubMed: 24934808 ( click the link to review the publication )

Cancer Res, 2014, 74(10):2803-15

PubMed: 24686171 ( click the link to review the publication )

Cancer Res, 2014, 74(11):3127-36

PubMed: 24755468 ( click the link to review the publication )

J Cell Biol, 2014, 205(6):771-80

PubMed: 24934156 ( click the link to review the publication )

Cell Death Differ, 2014, 21(12):1838-51

PubMed: 25034784 ( click the link to review the publication )

Mol Cancer, 2014, 13(1):159

PubMed: 24972933 ( click the link to review the publication )

Int J Cancer, 2014, 135(12):2950-61

PubMed: 24771510 ( click the link to review the publication )

Eur J Cancer, 2014, 51(1):1-8

PubMed: 25466507 ( click the link to review the publication )

Cancer Lett, 2014, 343(2):286-94

PubMed: 24120758 ( click the link to review the publication )

Br J Cancer, 2014, 110(9):2224-31

PubMed: 24691427 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1126

PubMed: 24625985 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1013

PubMed: 24457957 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1580

PubMed: 25522274 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(4):926-37

PubMed: 24482380 ( click the link to review the publication )

Br J Haematol, 2014, 167(5):639-50

PubMed: 25155625 ( click the link to review the publication )

J Biomed Nanotechnol, 2014, 10(4):717-23

PubMed: 24734524 ( click the link to review the publication )

J Biomed Nanotechnol, 2014, 10(4):717-23

PubMed: 24734524 ( click the link to review the publication )

J Am Heart Assoc, 2014, 3(1):e000520

PubMed: 24572252 ( click the link to review the publication )

J Nutr Biochem, 2014, 25(5):515-25

PubMed: 24613086 ( click the link to review the publication )

J Cell Sci, 2014, 127(Pt13):2898-909

PubMed: 24806960 ( click the link to review the publication )

J Virol, 2014, 87(23):13035-41

PubMed: 24027330 ( click the link to review the publication )

Eur J Immunol, 2014, 44(6):1604-14

PubMed: 24643698 ( click the link to review the publication )

J Leukocyte Biol, 2014, 95(3):461-9

PubMed: 24231258 ( click the link to review the publication )
Cancer Gene Ther, 2014, 21(11):472-82

PubMed: 25323693 ( click the link to review the publication )

J Biol Chem, 2014, 289(17):11906-15

PubMed: 24570003 ( click the link to review the publication )

J Biol Chem, 2014, 289(20):14075-88

PubMed: 24711452 ( click the link to review the publication )

J Proteome Res, 2014, 13(5):2223-38

PubMed: 24669782 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(19):3570-8

PubMed: 25022755 ( click the link to review the publication )

Am J Physiol Cell Physiol, 2014, 307(9):C774-87

PubMed: 25143351 ( click the link to review the publication )

J Biomed Mater Res A, 2014, 10.1002/jbm.a.35286

PubMed: 25046528 ( click the link to review the publication )

Hematol Oncol, 2014, 10.1002/hon.2179

PubMed: 25394177 ( click the link to review the publication )

Neurotoxicology, 2014, 42:33-48

PubMed: 24705302 ( click the link to review the publication )

Cancer Chemoth Pharm, 2014, 73(1):69-77

PubMed: 24190701 ( click the link to review the publication )

Cancer Chemoth Pharm, 2014, 10.1007/s00280-014-2451-7

PubMed: 24842158 ( click the link to review the publication )

PLoS One, 2014, 9(6):e99211

PubMed: 24911872 ( click the link to review the publication )

PLoS One, 2014, 9(3):e89848

PubMed: 24595136 ( click the link to review the publication )

PLoS One, 2014, 9(9):e107009

PubMed: 25255316 ( click the link to review the publication )

Mol Cell Biochem, 2014, 398(1-2):165-73

PubMed: 25292312 ( click the link to review the publication )

J Nanopart Res, 2014, 42:33-48

PubMed: http://link.springer.com/article/10.1007/s11051-01 ( click the link to review the publication )

Biosciences biotechnology research asia, 2014, 10.13005bbra.1309

PubMed: ( click the link to review the publication )

Sci Rep, 2014, 4:5896

PubMed: 25077633 ( click the link to review the publication )

Blood, 2013, 123(5):706-16

PubMed: 24319254 ( click the link to review the publication )

Hepatology, 2013, 57(2):625-36

PubMed: 22991197 ( click the link to review the publication )

Nat Chem Biol, 2013, 10(1):61-8

PubMed: 24292069 ( click the link to review the publication )

Nat Protoc, 2013, 8(6):1155-68

PubMed: 23702832 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(20):5591-601

PubMed: 24004671 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 110(9):3501-6

PubMed: 23382202 ( click the link to review the publication )
Cancer Res, 2013, 74(1):56-67

PubMed: 24310398 ( click the link to review the publication )

Mucosal Immunol, 2013, 7(4):857-68

PubMed: 24280938 ( click the link to review the publication )

Breast Cancer Res, 2013, 15(6):R107

PubMed: 24207099 ( click the link to review the publication )

Free Rad Biol Med, 2013, 65:778-88

PubMed: 23973637 ( click the link to review the publication )

Exp Mol Med, 2013, 45:e50

PubMed: 24158003 ( click the link to review the publication )

Pain, 2013, 154(11):2432-40

PubMed: 23891899 ( click the link to review the publication )

Expert Opin Drug Deliv, 2013, 10(10):1345-52

PubMed: 23937147 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(7):1299-309

PubMed: 23657945 ( click the link to review the publication )

Mol Oncol, 2013, 7(6):1012-8

PubMed: 23916134 ( click the link to review the publication )

ACS Chem Biol, 2013, 8(3):578-87

PubMed: 23198928 ( click the link to review the publication )

Gynecol Oncol, 2013, 128(2):383-90

PubMed: 23107612 ( click the link to review the publication )

J Virol, 2013, 87(21):11872-83

PubMed: 23986594 ( click the link to review the publication )

Mol Cell Biol, 2013, 33(12):2375-87

PubMed: 23572559 ( click the link to review the publication )

Mol Biol Cell, 2013, 35:215-22

PubMed: 24145151 ( click the link to review the publication )

Clin Exp Metastasis, 2013, 30(4):407-15

PubMed: 23412907 ( click the link to review the publication )

Retrovirology, 2013, 10(1):120

PubMed: 24156270 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2013, 139(9):1551-62

PubMed: 23877657 ( click the link to review the publication )

Toxicol Lett, 2013, 223(2):109-15

PubMed: 24055520 ( click the link to review the publication )

PLoS One, 2013, 8(9):e75280

PubMed: 24086494 ( click the link to review the publication )

PLoS One, 2013, 8(12):e82053

PubMed: 24312627 ( click the link to review the publication )

Eur J Haematol, 2013, 91(4):339-46

PubMed: 23869695 ( click the link to review the publication )

Leuk Res, 2013, 37(10):1302-8

PubMed: 23896061 ( click the link to review the publication )

J Int Med Res, 2013, 41(5):1505-19

PubMed: 23975859 ( click the link to review the publication )

Curr Protoc Chem Biol, 2013, 5(3):195-212

PubMed: 24391083 ( click the link to review the publication )
Blood, 2012, 119(24):5772-81

PubMed: 22538852 ( click the link to review the publication )

Blood, 2012, 119(11):2579-89

PubMed: 22262760 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(17):4669-81

PubMed: 22806876 ( click the link to review the publication )

Br J Pharmacol, 2012, 168(8):1868-77

PubMed: 23194305 ( click the link to review the publication )

Cancer Lett, 2012, 316(1):77-84

PubMed: 22082529 ( click the link to review the publication )

J Invest Dermatol, 2012, 132(5):1487-96

PubMed: 22377766 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e295

PubMed: 22495350 ( click the link to review the publication )

FASEB J, 2012, 26(5):1855-65

PubMed: 22345405 ( click the link to review the publication )

Mol Cancer Ther, 2012, 11(11):2321-30

PubMed: 22964485 ( click the link to review the publication )

Mol Cancer Ther, 2012, 11(10):2243-53

PubMed: 22933706 ( click the link to review the publication )

Br J Haematol, 2012, 157(6):718-31

PubMed: 22533681 ( click the link to review the publication )

J Virol, 2012, 86(18):10112-22

PubMed: 22787216 ( click the link to review the publication )

J Virol, 2012, 86(24):13360-70

PubMed: 23015717 ( click the link to review the publication )

Am J Physiol Endocrinol Metab, 2012, 303(3):E410-21

PubMed: 22669242 ( click the link to review the publication )

J Biol Chem, 2012, 287(13):10344-54

PubMed: 22318734 ( click the link to review the publication )

J Biol Chem, 2012, 288(2):1125-34

PubMed: 23209294 ( click the link to review the publication )

J Biol Chem, 2012, 288(4):2721-33

PubMed: 23209292 ( click the link to review the publication )

J Biol Chem, 2012, 287(41):34722-9

PubMed: 22910913 ( click the link to review the publication )

J Pharmacol Exp Ther, 2012, 343(1):184-97

PubMed: 22787116 ( click the link to review the publication )

Prostate, 2012, 72(10):1140-9

PubMed: 22127954 ( click the link to review the publication )

Cell Cycle, 2012, 11(9):1804-17

PubMed: 22510564 ( click the link to review the publication )

BMC Cancer, 2012, 12:541

PubMed: 23171055 ( click the link to review the publication )

Biol Reprod, 2012, 87(2):44

PubMed: 22592496 ( click the link to review the publication )

PLoS One, 2012, 7(1):e29541

PubMed: 22235305 ( click the link to review the publication )
PLoS One, 2012, 7(4):e34684

PubMed: 22514654 ( click the link to review the publication )

Exp Mol Pathol, 2012, 93(1):99-110

PubMed: 22475623 ( click the link to review the publication )

Steroids, 2012, 77(11):1025-32

PubMed: 22683670 ( click the link to review the publication )

J Biomol Screen, 2012, 17(9):1231-42

PubMed: 22927676 ( click the link to review the publication )

J Biomol Screen, 2012, 17(5):572-80

PubMed: 22357874 ( click the link to review the publication )

Biochem Cell Biol, 2012, 90(2):224-31

PubMed: 22397456 ( click the link to review the publication )

Saint Louis University, 2012, 2012/0270829

PubMed: ( click the link to review the publication )

Sarcoma, 2012, 2012:805614

PubMed: 22919280 ( click the link to review the publication )

Blood, 2011, 118(14):3922-31

PubMed: 21841164 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(16):5311-21

PubMed: 21724551 ( click the link to review the publication )

Development, 2011, 138(14):2903-8

PubMed: 21653611 ( click the link to review the publication )

Br J Haematol, 2011, 155(5):588-98

PubMed: 21950728 ( click the link to review the publication )

J Biol Chem, 2011, 286(18):16018-29

PubMed: 21454483 ( click the link to review the publication )

Exp Cell Res, 2011, 317(18):2671-82

PubMed: 21871886 ( click the link to review the publication )

Int Immunopharmacol, 2011, 11(12):2242-5

PubMed: 21979495 ( click the link to review the publication )

PLoS One, 2011, 6(8):e23712

PubMed: 21887304 ( click the link to review the publication )

Cell Biochem Biophys, 2011, 60(3):173-85

PubMed: 21132543 ( click the link to review the publication )

University of Porto, 2011, Mireia Vila Gasull

PubMed: ( click the link to review the publication )

Glia, 2010, 58(16):1961-76

PubMed: 20830808 ( click the link to review the publication )

Carcinogenesis, 2010, 31(11):1948-55

PubMed: 20837598 ( click the link to review the publication )

J Virol, 2010, 84(18):9439-51

PubMed: 20592098 ( click the link to review the publication )

J Biol Chem, 2010, 285(52):41074-86

PubMed: 20956535 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Description

Bortezomib (PS-341) is a potent 20S proteasome inhibitor with K_i of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.

Targets

20S proteasome ^[1]
(Cell-free assay)

0.6 nM(Ki)

In vitro

Bortezomib, a boronic acid dipeptide, is a highly selective, reversible inhibitor of the 26S proteasome which primarily functions in the degradation of mis-folded proteins and is essential for the regulation of the cell cycle. Exposure to Bortezomib has been shown to stabilize p21, p27, and p53, as well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor κB-α, which prevents activation of nuclear factor κB-induced cell survival pathways. Bortezomib also promotes the activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum stress response. Alteration of the levels of these cellular proteins leads to inhibition of proliferation, migration, and promotion of apoptosis of cancer cells. ^[2] Bortezomib is shown to penetrate into cells and inhibit proteasome-mediated intracellular proteolysis of long-lived proteins with a concentration that inhibits 50% of the proteolysis of ∼0.1 μM. The average growth inhibition of 50% value for Bortezomib across the entire panel of 60 cancer cell lines derived from multiple human tumors from the US National Cancer Institute (NCI) is 7 nM. Treatment of PC-3 cells with Bortezomib (100 nM) for 8 h results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1. Bortezomib kills PC-3 cells at 24 and 48 hr with IC50 of 100 and 20 nM, respectively. Bortezomib induces nuclear condensation at 16–24 hr after treatment. Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr. ^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
MCF-7	M1zsfWN6fG:2b4jpZ{BCe3OjeR?=	NXvGbIpJPTBizszN	MVm0PEBp	NUn0cVJXTE2VTx?=	Mnv1T4ltdHNiY3XscJMh[nlibX;y[UB1cGGwIEm5KS=>	NFXrNWMyODR7OU[0Ny=>
OVCA 429	NVnR[5IzTnWwY4Tpc44hSXO\|YYm=	M{\R[lMxOCCwTR?=	NEnQZ\|g1QCCq	MWPEUXNQ	NILaVYlFcXO{dYD0d{BqdnSjY4SgcZVtfGmlZXzseYxieiC2dX3vdkB{eGincn;p[JM>	NHvoPG8yODl7OUe2Oi=>
RPMI8226	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVOxNFAhdk1?	Mn;COFghcA>?	M{fqemROW09?	M2jFfWlEPTB;M{Cgcm0>	MXmxNVMxPjR6OR?=
Dox40	Ml2xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVv4dW5pOTByIH7N	Mn;wOFghcA>?	MVPEUXNQ	M3z3OGlEPTB;NECgcm0>	MVWxNVMxPjR6OR?=
MR20	NYTMR5NtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHywWpQyODBibl2=	NFLCOlU1QCCq	NXzERpA6TE2VTx?=	MXPJR\|UxRTJyIH7N	MoLKNVE{ODZ2OEm=
LR5	MlSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3JeIptOTByIH7N	NVTwZ4M6PDhiaB?=	MoLuSG1UVw>?	MX\JR\|UxRTJyIH7N	NXntd2tMOTF\|ME[0PFk>
U266	NXnmbmEyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmnTNVAxKG6P	MUe0PEBp	MmPrSG1UVw>?	NXTBVJVXUUN3ME2zJI5O	MUGxNVMxPjR6OR?=
IM-9	NHHlTJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{C2cFExOCCwTR?=	NY\Q[ZRjPDhiaB?=	NHzxUGZFVVOR	NVnwdFNHUUN3ME22JI5O	Mn72NVE{ODZ2OEm=
Hs Sultan	M4rQcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn32NVAxKG6P	M3jxUlQ5KGh?	NILJ[HBFVVOR	MVLJR\|UxRTJyIH7N	M1u5cVEyOzB4NEi5
PAM-LY2	MnHCSpVv[3Srb36gRZN{[Xl?	MWKxNFAhdk1?	MYWxNkBp	MluySG1UVw>?	MY\Jcohq[mm2czDOSk3PwkJiYXP0bZZifGmxbh?=	NVvib5pvOTF\|NUC5NVM>
PAM 212	MkX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1XTS\|ExOCCwTR?=	MWG3NkBp	NEfHTJJFVVOR	MVrJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>?	MXixNVM2ODlzMx?=
PAM-LY2	MnfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVrzT4I3OTByIH7N	M3;1cFczKGh?	NITYNlBFVVOR	NGfVUWJKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?=	MnXUNVE{PTB7MUO=
B4B8	NIe4NplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX[xNFAhdk1?	NFzOWoY4OiCq	MX3EUXNQ	NETRd4FKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?=	NFr5U2syOTN3MEmxNy=>
B7E3	M2rne2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWrtdYhrOTByIH7N	MmTXO\|IhcA>?	NIPNRYVFVVOR	MoSzTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl?	MmnHNVE{PTB7MUO=
UM-SCC-9	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF;0VFkyODBibl2=	NXnobYpLPzJiaB?=	MkLpSG1UVw>?	MYPJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>?	MlHTNVE{PTB7MUO=
UM-SCC-11B	M2HqSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVqxNFAhdk1?	NUW0b\|FrPzJiaB?=	M{\0OmROW09?	MnXyTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl?	MXuxNVM2ODlzMx?=
H460	MkfVSpVv[3Srb36gRZN{[Xl?	M3TBWlExKM7:TR?=	NEn3RWYzPCCq	NFnlSWJFVVOR	MYDJcoR2[2W\|IFLjcE0zKHCqb4PwbI9zgWyjdHnvckBidmRiY3zlZZZi\2ViY3;ydoVt[XSnZDD3bZRpKEd{LV2gdIhie2ViYYLy[ZN1	NHjVcYsyOjR7MkGxOy=>
U266	M1P4PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlnJOVAxKG6pL33s	MV60PEBp	NInUe25FVVOR	MUjJcohq[mm2czDj[YxtKGe{b4f0bC=>	MYmxNlY{OTZzOR?=
ARH77	NX;iW3ByT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHfhOGY2ODBibnevcYw>	NH7ERm81QCCq	M17JV2ROW09?	MmHVTY5pcWKrdIOgZ4VtdCCpcn;3eIg>	NE\BUGoyOjZ\|MU[xPS=>
WAD-1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPZO2o2ODBibnevcYw>	MXW0PEBp	NIjFeYtFVVOR	MWnJcohq[mm2czDj[YxtKGe{b4f0bC=>	NGn6cGMyOjZ\|MU[xPS=>
U266/LR7	MofqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGfoVm02ODBibnevcYw>	M1vafVQ5KGh?	NXvWOplJTE2VTx?=	NGOxRWFKdmirYnn0d{Bk\WyuIHfyc5d1cA>?	M3;kSFEzPjNzNkG5
U266/dox4	NW\BXI16T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm\xOVAxKG6pL33s	MlWxOFghcA>?	M3r4UGROW09?	MWLJcohq[mm2czDj[YxtKGe{b4f0bC=>	MXyxNlY{OTZzOR?=
RPMI8226/LR5	NWe0[WpnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3XkN\|UxOCCwZz;tcC=>	NVrkZVV{PDhiaB?=	M1v1NmROW09?	Ml64TY5pcWKrdIOgZ4VtdCCpcn;3eIg>	MmDnNVI3OzF4MUm=
H460	NHGzV45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2G0ZVExKM7:TR?=	MX63NkBp	MWDEUXNQ	NF\ofpBKSzVyPUGwNEBvVQ>?	NWHSZ4psOTJ4M{G2NlA>
H358	M1jGeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn:1NVAh\|ryP	NVPDOlB{PzJiaB?=	NV\D[4NLTE2VTx?=	M3zY[WlEPTB;N{Cgcm0>	MUWxNlY{OTZ{MB?=
H322	M37xR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkjpNVAh\|ryP	MoriO\|IhcA>?	NV30PYx5TE2VTx?=	MWrJR\|UxRTZ{MDDuUS=>	M4XnPVEzPjNzNkKw
H460	NHvUVXZHfW6ldHnvckBCe3OjeR?=	M{T5bFExOCCwTR?=	NUfQcnVGOjRiaB?=	NUC1dWNLTE2VTx?=	NXn5doNQUW6mdXPld{BIOi2PLYDoZZNmKGG{cnXzeEBidmRidIXieYxqdiCjc4PlcYJtgS2maYPhd5NmdWKueR?=	M{PMXlEzPjNzNkKw
LNCap-Pro5	NHnSXWFHfW6ldHnvckBCe3OjeR?=	M2rnXFEh\|ryP	M4TrTVQhcA>?	M1W1TmROW09?	M{LLd3N1[WKrbHn6[ZMheDV\|	MnHxNVQ3OTJ3M{K=
T29	MnSyRZBweHSxc3nzJGF{e2G7	M{HF[lUxKG6P	MoTJOFghcCB?	MYLEUXNQ	NH\4ZYNKdmS3Y3XzJINmdGxiYYDvdJRwe2m\|	M1TRW\|E3Pzd6MUe5
T29Kt1	NH\tWWRCeG:ydH;zbZMhSXO\|YYm=	NX35empEPTBibl2=	MlqzOFghcCB?	Ml\wSG1UVw>?	MUnJcoR2[2W\|IHPlcIwh[XCxcITvd4l{	MW[xOlc4QDF5OR?=
HCT116	MVzBdI9xfG:\|aYOgRZN{[Xl?	NF\FOpY2OCCwTR?=	M3PVVlQ5KGhi	NGjXSYxFVVOR	MYDJcoR2[2W\|IHPlcIwh[XCxcITvd4l{	MonXNVY4PzhzN{m=
HKe-3	M3iyPGFxd3C2b4Ppd{BCe3OjeR?=	MoXLOVAhdk1?	MWq0PEBpKA>?	NYTjNGdETE2VTx?=	NGnqSIJKdmS3Y3XzJINmdGxiYYDvdJRwe2m\|	M2fJUVE3Pzd6MUe5
NB-1691	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M33jUFEh\|ryP	NUPqToVFPzJiaB?=		NILzZ\|ZKdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hfG9iNTW=	MoDtNVc3QDl4OES=
CHLA-255	NYXHOo9mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXfZTmpsOSEQvF2=	Ml\RO\|IhcA>?		MXnJcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36geI8hOiV?	MknqNVc3QDl4OES=
SK-N-AS	NITIV5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXPzfYVLOSEQvF2=	NX\1eox4PzJiaB?=		MmPmTY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJJRwKDFyJR?=	NV;Gc\|VSOTd4OEm2PFQ>
NB-1691	NV;WXYtmTnWwY4Tpc44hSXO\|YYm=	MorDNVAhdk1?	M2jsflI1KGh?		M1vy[HNq\26rZnnjZY51dHlicnXkeYNmeyClZXzsd{BqdiC2aHWgS\|AwTzFicHjhd4U>	NGjIcG8yPzZ6OU[4OC=>
CHLA-255	M{SzcGZ2dmO2aX;uJGF{e2G7	NFLpeWwyOCCwTR?=	NFHNZpQzPCCq		NFewUoZOd2Snc4TsfUBz\WS3Y3XzJINmdGy\|IHnuJJRp\SCJMD;HNUBxcGG\|ZR?=	M{XqXlE4Pjh7Nki0
RPMI 8226	MWLGeY5kfGmxbjDBd5NigQ>?	M4nYUlIxKG6P	NVHWUWFsQCCq		M1rUR3Nq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6	NGDIRpIyQTR\|NkC1NC=>
MM.1S	MYfGeY5kfGmxbjDBd5NigQ>?	NVLDNZZYOjBibl2=	NEHXS2I5KGh?		M1f5U3Nq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6	M1TyclE6PDN4MEWw
U266	NWDVPXlETnWwY4Tpc44hSXO\|YYm=	NFjKR\|QzOCCwTR?=	MVm4JIg>		M2fiNHNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6	NW\mOGd5OTl2M{[wOVA>
OPM1	M{j5eWZ2dmO2aX;uJGF{e2G7	MUmyNEBvVQ>?	MoO3PEBp		M{nWenNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6	MV6xPVQ{PjB3MB?=
INA6	NYnqXmoxTnWwY4Tpc44hSXO\|YYm=	M1HnPVIxKG6P	Ml;yPEBp		MnnjV4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk>	MWqxPVQ{PjB3MB?=
OPM2	NV76cYRDTnWwY4Tpc44hSXO\|YYm=	M1;4OVIxKG6P	MVe4JIg>		MmjFV4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk>	MYGxPVQ{PjB3MB?=
RPMI 8226	MVnGeY5kfGmxbjDBd5NigQ>?	NGLRNmMzOCCwTR?=	Mn;EPEBp		M4XC[mlv\HWlZYOgSG5CKHO7boTo[ZNqew>?	NFHsTFgyQTR\|NkC1NC=>
BaF/3	M2q5SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVqxNFAhdk1?	M4L3OFQ5KGh?		Ml3aTWM2OD14LkKgcm0>	NF3nd5ozODNyNU[5Ni=>
BaF/3-p210	MmfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoDQNVAxKG6P	MlTJOFghcA>?		NH3mSHFKSzVyPUSuO{BvVQ>?	MUmyNFMxPTZ7Mh?=
TCC-S	NGDDRlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M37HTFExOCCwTR?=	NHe1doU1QCCq		NWmyNZhCUUN3ME2yMlghdk1?	NWTaNHZjOjB\|MEW2PVI>
BaF/3	M3\zeWZ2dmO2aX;uJGF{e2G7	NWnI[5lrPiCwTR?=	MlyxOFghcA>?		MlzsTY5lfWOnczDhJIdz\WG2IFexJINmdGxvY4njcIUh[XK{ZYP0	MlPVNlA{ODV4OUK=
BaF/3-p210	MWfGeY5kfGmxbjDBd5NigQ>?	MVS2JI5O	NXrxZW0{PDhiaB?=		MULJcoR2[2W\|IHGgd4xq\2i2IFexJINmdGxvY4njcIUh[XK{ZYP0	NX3ab2kxOjB\|MEW2PVI>
BaF/3-p210	M4\1e2Z2dmO2aX;uJGF{e2G7	M2TFSlYhdk1?	MXyyOEBp		NXO1XpdsWmWmdXPld{B1cGVicHjvd5Bpd3K7bHH0bY9vKGGwZDD0bIUh[WO2aY\peJkhd2ZiUnK=	NVr6SFJMOjB\|MEW2PVI>
Raji	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVuxJO69VQ>?	MWSyOEBp		MorJVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi	M1LuUFIyOTdyOUi4
LCL-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml;hNUDPxE1?	M364PVI1KGh?		MmexVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi	MUiyNVE4ODl6OB?=
LCL-2	NF3j[oZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWXjWVVNOSEQvF2=	M1P3Z\|I1KGh?		NWTRTWk4WmWmdXPld{Bk\WyuII\pZYJqdGm2edMg	NFXWeHozOTF5MEm4PC=>
BJAB	NUXTfW1oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUHGcnpCOSEQvF2=	NYPvUmo2OjRiaB?=		NWH1ZVJuWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg	MljsNlEyPzB7OEi=
SNT-13	M4\NU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIG2RXUyKM7:TR?=	NWLMUVVNOjRiaB?=		NEHLdIFT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC=	NUC3RYFsOjFzN{C5PFg>
SNT-16	NYLPeHlqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1vNblEh\|ryP	NW\ONIxVOjRiaB?=		Mn\TVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi	MmewNlEyPzB7OEi=
Jurkat	NEPEeYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkO2NUDPxE1?	Mof4NlQhcA>?		M13FVnJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?=	NV;zcGRuOjFzN{C5PFg>
KAI-3	NES2dmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVixJO69VQ>?	NXiwTpRpOjRiaB?=		MkT3VoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi	MXOyNVE4ODl6OB?=
SNK-6	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlOwNUDPxE1?	MYmyOEBp		M3HDfHJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?=	M{S3WVIyOTdyOUi4
KHYG-1	NYS4UFdkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3\LZVEh\|ryP	M4L1V\|I1KGh?		MYDS[YR2[2W\|IHPlcIwhfmmjYnnsbZR6yqB?	MoPHNlEyPzB7OEi=
SNT-16	MmXqRZBweHSxc3nzJGF{e2G7	NIP3RmsyKM7:TR?=	MVG2JIg>		M4DLbGlv\HWlZYOgZ4VtdCCjcH;weI9{cXN?	M3LIPVIyOTdyOUi4
Jurkat	NELMOW9CeG:ydH;zbZMhSXO\|YYm=	NHnkbokyKM7:TR?=	NXnPd5RvPiCq		MmDRTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?	MoXTNlEyPzB7OEi=
KAI-3	MVPBdI9xfG:\|aYOgRZN{[Xl?	NETqSW8yKM7:TR?=	MnLQOkBp		NGSwRWpKdmS3Y3XzJINmdGxiYYDvdJRwe2m\|	NYLCVZo5OjFzN{C5PFg>
KHYG-1	MXTBdI9xfG:\|aYOgRZN{[Xl?	MV:xJO69VQ>?	MWC2JIg>		MWPJcoR2[2W\|IHPlcIwh[XCxcITvd4l{	NWLsZo1zOjFzN{C5PFg>
SNT-13	NHnoW5FCdnSrdnnyZYwhSXO\|YYm=	M4TZO\|Eh\|ryP	MY[yOEBp		MWLJcoR2[2W\|IHz5eIlkKGmwZnXjeIlwdiCxZjDFRnY>	Mnf4NlEyPzB7OEi=
SNT-16	NGfqb4lCdnSrdnnyZYwhSXO\|YYm=	NF\1eoEyKM7:TR?=	NFuzN2wzPCCq		NWPKb3E3UW6mdXPld{BtgXSrYzDpcoZm[3Srb36gc4YhTUKY	MlzBNlEyPzB7OEi=
KAI-3	MWPBcpRqfmm{YXygRZN{[Xl?	MXmxJO69VQ>?	M3r5elI1KGh?		NVfYeYlPUW6mdXPld{BtgXSrYzDpcoZm[3Srb36gc4YhTUKY	M3XV[FIyOTdyOUi4
SNK-6	M4DsPGFvfGm4aYLhcEBCe3OjeR?=	Mkf0NUDPxE1?	MV6yOEBp		M2G4b2lv\HWlZYOgcJl1cWNiaX7m[YN1cW:wIH;mJGVDXg>?	NYTnSVExOjFzN{C5PFg>
RAW 264.7	M3;V[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGDydJYyODBibl2=	MYm0PEBp		NWH1NVBTWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg	MoDiNlI1OjdzNUS=
A375	Mli3RZBweHSxc3nzJGF{e2G7	MlfFNVAhdk1?	M1X1RVI1KGh?		MVLJcoR2[2W\|IHPlcIwh[XCxcITvd4l{	MXOyN\|A4QTB6Mx?=
BLM	Mo\kRZBweHSxc3nzJGF{e2G7	NHz1W2UyOCCwTR?=	MWWyOEBp		NXnye\|J1UW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	MXmyN\|A4QTB6Mx?=
A375	Ml7jRZV1d3CqYXf5JGF{e2G7	M4Hoe\|ExKG6P	NXO3[nJUOTJiaB?=		MkPjTY5lfWOnczDmc5Ju[XSrb36gc4Yh[XW2b4DoZYdwe2:vZYO=	NEPGN3kzOzB5OUC4Ny=>
BLM	Mm\1RZV1d3CqYXf5JGF{e2G7	NInOdVEyOCCwTR?=	NWCzc5N5OTJiaB?=		NV\1PIJjUW6mdXPld{Bnd3KvYYTpc44hd2ZiYYX0c5Bp[Wexc3;t[ZM>	MWqyN\|A4QTB6Mx?=
H1299	NHXWco5CeG:ydH;zbZMhSXO\|YYm=	M37PVVgxKG6P	MYKyOEBp	MUTEUXNQ	MWXT[Y5{cXSrenXzJG5US0yFIHPlcIx{KHSxIF3TR{1l\XKrdnXkJIlEQS2rbnT1Z4VlKGGyb4D0c5Nqew>?	NWTadYVNOjV\|MkO2PVM>
Hut-78	MoHJSpVv[3Srb36gRZN{[Xl?	MVyxNFAhdk1?	MWOyOEBp	MUPEUXNQ	MULEc5dvemWpdXzheIV{KFSJRj5OtlEh[W6mIFnMMVExKGW6cILld5Nqd25?	MX[yOVY5OTN\|NR?=
H9	NVLRW20xTnWwY4Tpc44hSXO\|YYm=	MYixNFAhdk1?	M4roVlI1KGh?	M3jYRWROW09?	MVHEc5dvemWpdXzheIV{KFSJRj5OtlEh[W6mIFnMMVEyKGW6cILld5Nqd25?	NXXhTXRrOjV4OEGzN\|U>
HH	NXfiWFBLTnWwY4Tpc44hSXO\|YYm=	MUKxNFAhdk1?	NGTiOZUzPCCq	NV6ySZhLTE2VTx?=	Ml3Z[I94dnKnZ4XsZZRmeyCWR1[t{tIyKGGwZDDJUE0yOiCneIDy[ZN{cW:w	NHrnWpQzPTZ6MUOzOS=>
Hut-78	NIXEd\|hOcWe{YYTpc44hSXO\|YYm=	NF;TSIMyODBibl2=	M2S0bFI1KGh?	MYPEUXNQ	M4focXJm\HWlZYOgZ4VtdCCvaXfyZZRqd25iYomgPFDjiJN7MDW=	Mnu4NlU3QDF\|M{W=
HH	NF\UVIhOcWe{YYTpc44hSXO\|YYm=	NWjSXpg3OTByIH7N	M4PpcVI1KGh?	M4\BOmROW09?	NHnrUJFT\WS3Y3XzJINmdGxibXnndoF1cW:wIHL5JFgx6oDVOUGl	NISwc5kzPTZ6MUOzOS=>
U937	NWr5flFMTnWwY4Tpc44hSXO\|YYm=	MlHvNVAxKG6P	NYfGPJZqPiCq		MVHJcoR2[2W\|IFnMMVgh\XiycnXzd4lwdiCrbjDMVHMue3SrbYXsZZRm\CCXOUO3JI1i[3KxcHjh[4V{	NGHoSlczPTd7MUS3Oy=>
human PBMC	MYjGeY5kfGmxbjDBd5NigQ>?	MXyxNFAhdk1?	NGrE[44zPCCq		M3m2Smlv\HWlZYOgTWwuQCC{ZXzlZZNm	MYeyOVc6OTR5Nx?=
ES6	NFy2ZoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M37OXGlEPTB;MD6wNFIyKG6P	NYfHc5FFW0GQR1XS
SK-UT-1	MkfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHHrOndKSzVyPUCuNVY{KG6P	MYfTRW5ITVJ?
SH-4	MnrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3\kTWlEPTB;MD6xO\|Mhdk1?	MWTTRW5ITVJ?
TE-9	MmXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4fVS2lEPTB;MD6xPFIhdk1?	NUPCemNrW0GQR1XS
A253	M2LzR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3;4[mlEPTB;MD6yNFghdk1?	NHvZc29USU6JRWK=
no-10	MkfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mnv4TWM2OD1yLkKxJI5O	NVzxVZpCW0GQR1XS
MMAC-SF	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV3sdWFoUUN3ME2wMlIyPiCwTR?=	MVPTRW5ITVJ?
A101D	NV;0bGdET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGTzO4VKSzVyPUCuNlI2KG6P	MmLHV2FPT0WU
NTERA-S-cl-D1	NH3t[FlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHjGOJZKSzVyPUCuNlQ{KG6P	NYruTpNjW0GQR1XS
8-MG-BA	NGH2TnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1LubWlEPTB;MD6yOUBvVQ>?	NVO1TIRnW0GQR1XS
KNS-42	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHz2dllKSzVyPUCuNlU5KG6P	M4K5RnNCVkeHUh?=
LXF-289	M{PZT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIn4WFRKSzVyPUCuNlY6KG6P	NEDOblNUSU6JRWK=
OVCAR-4	NELWTVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M17vWWlEPTB;MD6yPFkhdk1?	MonDV2FPT0WU
LOUCY	M1vpUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1r5SWlEPTB;MD6yPVMhdk1?	NFTKbHVUSU6JRWK=
BB65-RCC	NFPR[pJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NInRTJFKSzVyPUCuN\|A1KG6P	M4HEUXNCVkeHUh?=
D-542MG	Mn;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV3JR\|UxRTBwM{K5JI5O	NHnSb4RUSU6JRWK=
ONS-76	MnyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoX3TWM2OD1yLkOzJI5O	NEjyTWdUSU6JRWK=
BB30-HNC	NWX1cIR7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXP5bm1XUUN3ME2wMlM{PSCwTR?=	M3PIcHNCVkeHUh?=
KS-1	NX:zcJVTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVzJR\|UxRTBwM{Sgcm0>	NEjVOoZUSU6JRWK=
A388	NUTNTZVbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnW3TWM2OD1yLkO1OkBvVQ>?	NGjvUJBUSU6JRWK=
ES8	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnrkTWM2OD1yLkSgcm0>	NFLNNFhUSU6JRWK=
MZ2-MEL	NILUb\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2C2[mlEPTB;MD60NFchdk1?	Mn3JV2FPT0WU
HCC2998	NV7FXY5RT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEWzbWFKSzVyPUCuOFEzKG6P	MUjTRW5ITVJ?
D-247MG	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFXIWXNKSzVyPUCuOFE{KG6P	M{PkPXNCVkeHUh?=
ACN	NV36bIdkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFzROGVKSzVyPUCuOFE4KG6P	NFfmTFRUSU6JRWK=
LB2518-MEL	NXjyUZlwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4DCT2lEPTB;MD60NlUhdk1?	MV7TRW5ITVJ?
ES1	NW[2d2RFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3uyeGlEPTB;MD60N{BvVQ>?	NEWzR4RUSU6JRWK=
HCE-T	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF\sOHVKSzVyPUCuOFM6KG6P	MnPuV2FPT0WU
OS-RC-2	NX;VR4trT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmHCTWM2OD1yLkS0JI5O	MV\TRW5ITVJ?
MFH-ino	NH;hOItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoH1TWM2OD1yLkS0N{BvVQ>?	MVPTRW5ITVJ?
OCUB-M	M3n1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3;VfGlEPTB;MD60OFchdk1?	MXvTRW5ITVJ?
CP66-MEL	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlXsTWM2OD1yLkS3N{BvVQ>?	M{HP[nNCVkeHUh?=
LB771-HNC	NHTtcW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF7LeZNKSzVyPUCuOFc1KG6P	NHf5WlZUSU6JRWK=
DSH1	MnjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYnJR\|UxRTBwNEigcm0>	NYWzNYJGW0GQR1XS
HUTU-80	NGLOTm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn;LTWM2OD1yLkWzN{BvVQ>?	M3S4SnNCVkeHUh?=
CESS	NYfTUWs6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkWyTWM2OD1yLkWzPEBvVQ>?	NWTPdIE5W0GQR1XS
NCI-H747	MkDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIDJPXBKSzVyPUCuOVM6KG6P	NX;HU3o1W0GQR1XS
HT-144	NELz[5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX7JR\|UxRTBwNUe2JI5O	NELFR4FUSU6JRWK=
COLO-829	M4[zdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2j3SmlEPTB;MD62NVQhdk1?	MWrTRW5ITVJ?
A4-Fuk	NVPvV4VZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHLMNZNKSzVyPUCuOlI{KG6P	NY\MN\|Z6W0GQR1XS
GI-ME-N	NFfG[IlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkHpTWM2OD1yLk[zOEBvVQ>?	M1\pfXNCVkeHUh?=
LB831-BLC	NYr1cldCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVHSTW1PUUN3ME2wMlY1OSCwTR?=	NUf2SoNHW0GQR1XS
HOP-62	NV3VNodCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{LvWGlEPTB;MD62OFchdk1?	MoizV2FPT0WU
BB49-HNC	M3L5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWPkUWFwUUN3ME2wMlY2OiCwTR?=	NIHifmRUSU6JRWK=
D-336MG	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2WyW2lEPTB;MD62OVchdk1?	Mn;uV2FPT0WU
TK10	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoPXTWM2OD1yLk[3PUBvVQ>?	NIDzNopUSU6JRWK=
Ramos-2G6-4C10	Mkf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFn5[JZKSzVyPUCuOlk{KG6P	MmfKV2FPT0WU
LB373-MEL-D	M{LWUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVjJR\|UxRTBwNzDuUS=>	M2nRSHNCVkeHUh?=
SF126	MkHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MULJR\|UxRTBwN{CxJI5O	NGjJOnRUSU6JRWK=
UACC-257	M1zEUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NG\oS41KSzVyPUCuO\|Ehdk1?	NGrE[HlUSU6JRWK=
KINGS-1	Mlz3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV7JR\|UxRTBwN{KyJI5O	Mm\PV2FPT0WU
LS-513	NX;mb3l6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF[yU5ZKSzVyPUCuO\|M6KG6P	NFLjT3VUSU6JRWK=
GI-1	NV[yPFdoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml72TWM2OD1yLke2OEBvVQ>?	M2L4PHNCVkeHUh?=
ES7	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmjvTWM2OD1yLke2OkBvVQ>?	M1PSTHNCVkeHUh?=
LB2241-RCC	M4LCSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{DsfmlEPTB;MD64NFQhdk1?	NWnyOHJ3W0GQR1XS
D-263MG	NG[2NZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1XifmlEPTB;MD64NFchdk1?	MV\TRW5ITVJ?
SW684	M4nsR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1jwfGlEPTB;MD64NlEhdk1?	NWjleHRMW0GQR1XS
ML-2	NVn2bIFET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIPBVllKSzVyPUCuPFIyKG6P	NWjWfY5bW0GQR1XS
SK-LMS-1	NYTRVmd4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWjJR\|UxRTBwOEW0JI5O	M4XvdHNCVkeHUh?=
TE-5	M4nNVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MojtTWM2OD1yLki2OUBvVQ>?	NGDwbpFUSU6JRWK=
QIMR-WIL	NGfpXmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVfHTJdxUUN3ME2wMlg5QSCwTR?=	M2Hw[HNCVkeHUh?=
NCI-H1355	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHHTV45KSzVyPUCuPFk2KG6P	MU\TRW5ITVJ?
SNB75	NV[3cJlST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlHyTWM2OD1yLkmxNkBvVQ>?	Mm\UV2FPT0WU
RXF393	MkWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmHoTWM2OD1yLkmxOEBvVQ>?	MXvTRW5ITVJ?
IST-MEL1	NFTmOmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4r1SGlEPTB;MD65NVchdk1?	MkC3V2FPT0WU
SF268	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWrZOJZwUUN3ME2wMlkzOyCwTR?=	MmnVV2FPT0WU
KALS-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NULTfmdUUUN3ME2wMlkzPSCwTR?=	NGHwd3RUSU6JRWK=
HC-1	NGTKNWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3Hm[WlEPTB;MD65O\|Uhdk1?	NEfp[VBUSU6JRWK=
SW872	M4L3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{G4Z2lEPTB;MD65PVYhdk1?	NHjKTGxUSU6JRWK=
PSN1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYHuUWM2UUN3ME2xMlAyKG6P	MmWyV2FPT0WU
TE-1	NH;JRZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUSzNWZZUUN3ME2xMlA{KG6P	M2DPfnNCVkeHUh?=
TE-10	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWjBeoJWUUN3ME2xMlA{KG6P	MYrTRW5ITVJ?
RKO	M37RVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MonOTWM2OD1zLkC2JI5O	MUDTRW5ITVJ?
LC-2-ad	MnL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGXzO5pKSzVyPUGuNFghdk1?	M3\zfHNCVkeHUh?=
SK-MM-2	NF2wU\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVi4SoFSUUN3ME2xMlA6KG6P	Mkj3V2FPT0WU
VA-ES-BJ	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWL1cIVtUUN3ME2xMlA6KG6P	NF;oSlVUSU6JRWK=
MZ7-mel	NUfWUVVIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTFwMEmgcm0>	MYXTRW5ITVJ?
D-392MG	NU\iO3pbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGHhTlJKSzVyPUGuNUBvVQ>?	M4PvTHNCVkeHUh?=
CCRF-CEM	MmPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVXJR\|UxRTFwMUOgcm0>	NHOzW3lUSU6JRWK=
EM-2	MkG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mlu4TWM2OD1zLkG2JI5O	NWrRNJRbW0GQR1XS
HAL-01	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1nxemlEPTB;MT6xPEBvVQ>?	NWrY[3JTW0GQR1XS
TE-8	M3TZRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV\QWGJMUUN3ME2xMlE6KG6P	M3rHOnNCVkeHUh?=
NCI-H1882	NYO5VnFFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX;JR\|UxRTFwMjDuUS=>	MmrlV2FPT0WU
Daudi	M1T5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{TnUGlEPTB;MT6yNkBvVQ>?	NX\5ZmNSW0GQR1XS
BL-41	Mof2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml7OTWM2OD1zLkK1JI5O	NFu2TGFUSU6JRWK=
SR	NV[0V3lXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mmr5TWM2OD1zLkK1JI5O	M1PYRnNCVkeHUh?=
KM12	M3HjZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYPWWGVKUUN3ME2xMlI4KG6P	NF3DSXRUSU6JRWK=
K5	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVXJR\|UxRTFwMkigcm0>	NYPwXlY1W0GQR1XS
A3-KAW	MlfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1\VN2lEPTB;MT6yPEBvVQ>?	MX3TRW5ITVJ?
CMK	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoSxTWM2OD1zLkK5JI5O	MmTEV2FPT0WU
Calu-6	NIrwOVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2fITmlEPTB;MT6yPUBvVQ>?	Mnf4V2FPT0WU
IST-SL2	MlvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkPhTWM2OD1zLkOxJI5O	NInVS5hUSU6JRWK=
OPM-2	NEjPTFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWniZlJMUUN3ME2xMlM{KG6P	NGL2ZmFUSU6JRWK=
DU-4475	MoXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4rIc2lEPTB;MT6zOkBvVQ>?	MUHTRW5ITVJ?
ECC12	NILNblVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUTJR\|UxRTFwM{egcm0>	NF:xb5lUSU6JRWK=
L-540	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF;kXYZKSzVyPUGuN\|chdk1?	NHq4eGxUSU6JRWK=
CAS-1	MlvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIrrcoFKSzVyPUGuN\|chdk1?	NV2xeXplW0GQR1XS
PF-382	NVPDbFZzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1nuSmlEPTB;MT60O{BvVQ>?	MXHTRW5ITVJ?
LS-411N	M{nQSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUnoS3NxUUN3ME2xMlU{KG6P	NHHMOFJUSU6JRWK=
NCI-H69	MnnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3[2ZmlEPTB;MT61OEBvVQ>?	NV\OUm9NW0GQR1XS
NB12	NFnDZlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4XITmlEPTB;MT61OkBvVQ>?	MVzTRW5ITVJ?
HEL	MojCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{m4S2lEPTB;MT62NUBvVQ>?	MV\TRW5ITVJ?
GCIY	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTFwNkKgcm0>	NFrRN4hUSU6JRWK=
EHEB	M1O1VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkTzTWM2OD1zLk[3JI5O	NIfFeGFUSU6JRWK=
TGBC1TKB	M3XhfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml7yTWM2OD1zLkexJI5O	MoDBV2FPT0WU
KURAMOCHI	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NILi[5lKSzVyPUGuO\|Ihdk1?	Ml\nV2FPT0WU
U-266	NYfhPYlnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mlq1TWM2OD1zLke2JI5O	NGfrWnRUSU6JRWK=
LC4-1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV\YVHlwUUN3ME2xMlc6KG6P	NYm3UXZ6W0GQR1XS
NCI-H2126	NHvTSI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3vzeWlEPTB;MT64JI5O	MUXTRW5ITVJ?
NCI-H1092	NYnx[ZpvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml2zTWM2OD1zLkigcm0>	NXKxTGpsW0GQR1XS
GB-1	M{DFZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV65WYR2UUN3ME2xMlgyKG6P	NWLXTWZXW0GQR1XS
MV-4-11	M{LiOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M13wVGlEPTB;MT64NkBvVQ>?	MlnhV2FPT0WU
Becker	NE[xVotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWDJR\|UxRTFwOEOgcm0>	NUTmfI9yW0GQR1XS
MPP-89	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn7vTWM2OD1zLki5JI5O	NWTNZVVvW0GQR1XS
BE-13	NELOPY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NI\CdHVKSzVyPUGuPVMhdk1?	NVSxW3JlW0GQR1XS
697	M2\LT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF3UTZRKSzVyPUGuPVkhdk1?	MYjTRW5ITVJ?
NKM-1	M4TINWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIfWVmRKSzVyPUKgcm0>	NFrR[JRUSU6JRWK=
NB13	NWTwVHpIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3;3XGlEPTB;MjDuUS=>	NHraR3RUSU6JRWK=
LS-123	NIfDZo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3fFZmlEPTB;Mj6wNkBvVQ>?	NGezdJRUSU6JRWK=
NB17	Mn\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NU\ubXc2UUN3ME2yMlA1KG6P	NVLWdYRsW0GQR1XS
LAN-6	NXH6TZVxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MU\JR\|UxRTJwMEWgcm0>	M1m4e3NCVkeHUh?=
EW-24	MkXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHv4PGlKSzVyPUKuNFghdk1?	M2PYTXNCVkeHUh?=
NOS-1	M2TPc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHPRXHdKSzVyPUKuNVEhdk1?	NEHPeFFUSU6JRWK=
BL-70	M3TYTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXXJR\|UxRTJwMUKgcm0>	MorWV2FPT0WU
GT3TKB	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIL0bGZKSzVyPUKuNVIhdk1?	M4X4VXNCVkeHUh?=
HH	M1LrOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUfJR\|UxRTJwMUOgcm0>	M3LXenNCVkeHUh?=
KE-37	NF\KU2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1[1cmlEPTB;Mj6xN{BvVQ>?	M3LSbXNCVkeHUh?=
MOLT-4	NFPBd2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFPkOmFKSzVyPUKuNVMhdk1?	NYHEfZQ3W0GQR1XS
EKVX	NGn0WG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXHVdlJXUUN3ME2yMlE1KG6P	Ml\sV2FPT0WU
KGN	NVrhO49bT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{HIbGlEPTB;Mj6xOUBvVQ>?	NHrldZdUSU6JRWK=
ES4	M3iy[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVXJR\|UxRTJwMU[gcm0>	MoLIV2FPT0WU
SJSA-1	NFrMb2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUPJR\|UxRTJwMkGgcm0>	M1L4SXNCVkeHUh?=
KMOE-2	NU\SR\|JET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEDofXBKSzVyPUKuNlMhdk1?	M1LmenNCVkeHUh?=
NB5	MnvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3LWOmlEPTB;Mj6yO{BvVQ>?	NXfpbY1XW0GQR1XS
BC-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlK0TWM2OD1{LkOxJI5O	NXe5SW8zW0GQR1XS
NB10	NELDcVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmWxTWM2OD1{LkOyJI5O	NV\wUlJ4W0GQR1XS
RPMI-8226	MmnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{DS[WlEPTB;Mj6zOUBvVQ>?	MULTRW5ITVJ?
SCC-3	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYXxXFBCUUN3ME2yMlM4KG6P	NHL3[ZZUSU6JRWK=
ARH-77	M{HuOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVjQeoZQUUN3ME2yMlM5KG6P	NF6z[GxUSU6JRWK=
NCI-H748	NH7nRZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4jlW2lEPTB;Mj6zPUBvVQ>?	M2Wy[HNCVkeHUh?=
KU812	MoLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHLOeZVKSzVyPUKuOFIhdk1?	MkPDV2FPT0WU
NCI-H64	MlrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIrsbW5KSzVyPUKuOFQhdk1?	Mmf2V2FPT0WU
NB69	MnLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV25PJdJUUN3ME2yMlQ3KG6P	NGHEdmlUSU6JRWK=
KNS-81-FD	NFL5WIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTJwNEigcm0>	NHLHT41USU6JRWK=
LB1047-RCC	NWXBWGVlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWjJR\|UxRTJwNUegcm0>	MXLTRW5ITVJ?
EB-3	NGnRTWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NID5UYpKSzVyPUKuOlYhdk1?	NWTab\|lHW0GQR1XS
Mo-T	MoXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRTJwN{Sgcm0>	M4\PRXNCVkeHUh?=
EW-16	NIHZNGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NILzS2NKSzVyPUKuO\|Uhdk1?	NFjNVZpUSU6JRWK=
CTV-1	NEfmVY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2TVN2lEPTB;Mj64JI5O	NITwPFhUSU6JRWK=
ETK-1	NX7VOIdmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{f5XmlEPTB;Mj64OEBvVQ>?	NYW4Z3JTW0GQR1XS
C2BBe1	NIX5XFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm\kTWM2OD1{Lki5JI5O	MW\TRW5ITVJ?
MOLT-16	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml65TWM2OD1{Lki5JI5O	NIO3dHFUSU6JRWK=
SW954	MlvTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXTRbpUzUUN3ME2yMlkhdk1?	MmizV2FPT0WU
HT	M122[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmHFTWM2OD1\|LkCyJI5O	MXXTRW5ITVJ?
KARPAS-299	NE\ldYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEHxZ\|lKSzVyPUOuNFYhdk1?	NVu1b2s5W0GQR1XS
MONO-MAC-6	MkWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3jHWWlEPTB;Mz6xJI5O	NXKyO4dYW0GQR1XS
CGTH-W-1	NYDjOVJJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHnWUZNKSzVyPUOuNUBvVQ>?	NW\MW3VTW0GQR1XS
SK-PN-DW	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MljBTWM2OD1\|LkG0JI5O	MV;TRW5ITVJ?
CW-2	M2nKRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3PXV2lEPTB;Mz6yNUBvVQ>?	M3vUOXNCVkeHUh?=
SK-N-DZ	NF7pc3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2jsN2lEPTB;Mz6yOkBvVQ>?	M1XUZnNCVkeHUh?=
NEC8	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIj6c29KSzVyPUOuN\|Uhdk1?	MYHTRW5ITVJ?
LB996-RCC	Mon0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXP6UY97UUN3ME2zMlQhdk1?	NXPmd\|ZXW0GQR1XS
DB	NVT6OJJbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{e0e2lEPTB;Mz60NUBvVQ>?	MkHvV2FPT0WU
TE-15	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVjldodvUUN3ME2zMlQ{KG6P	Mm\jV2FPT0WU
COR-L88	NYK3Wnh{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWTIXo1rUUN3ME2zMlQ4KG6P	NHv4bHZUSU6JRWK=
LAMA-84	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEfTdo5KSzVyPUOuOFkhdk1?	MlrMV2FPT0WU
MEG-01	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH;0ZpZKSzVyPUOuOFkhdk1?	MlrzV2FPT0WU
LOXIMVI	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn3iTWM2OD1\|LkWgcm0>	NHrBRmRUSU6JRWK=
RPMI-8402	NILtWnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGKyR4JKSzVyPUOuOUBvVQ>?	NHfaXFRUSU6JRWK=
KARPAS-45	NYnDdIo2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmjBTWM2OD1\|LkW0JI5O	M{PLTXNCVkeHUh?=
HCC1187	MlnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRTNwNUSgcm0>	NVH2b2t[W0GQR1XS
MZ1-PC	M{f5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2X6eGlEPTB;Mz61OEBvVQ>?	NX3WOoRCW0GQR1XS
no-11	NHzvR\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmLZTWM2OD1\|LkW1JI5O	NXvRbYZGW0GQR1XS
EVSA-T	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmjlTWM2OD1\|Lk[gcm0>	Mn2wV2FPT0WU
DJM-1	NWPVVVBOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4HjdmlEPTB;Mz62N{BvVQ>?	M{Pme3NCVkeHUh?=
COLO-684	NEiyRo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHPyW\|NKSzVyPUOuOlYhdk1?	NVXxVo9iW0GQR1XS
NMC-G1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYG2XpZTUUN3ME2zMlY5KG6P	MUHTRW5ITVJ?
LC-1F	NHThc\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVPXfYVQUUN3ME2zMlc1KG6P	NXXOUZFDW0GQR1XS
RL95-2	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXXQPGE1UUN3ME2zMlc6KG6P	NXfZNWtLW0GQR1XS
COLO-320-HSR	NUjIWmlpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIrnWWJKSzVyPUOuPVIhdk1?	MXfTRW5ITVJ?
RCC10RGB	MnTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmDOTWM2OD1\|LkmzJI5O	M3rHVnNCVkeHUh?=
HD-MY-Z	NYn6WXd5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWHYe4FpUUN3ME2zMlk{KG6P	MljsV2FPT0WU
NCI-H2141	NGnzbW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2HTUGlEPTB;ND6wOUBvVQ>?	M4O2UHNCVkeHUh?=
K-562	NXX5N3p4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{PsZWlEPTB;ND6xNkBvVQ>?	NHfkPWpUSU6JRWK=
NCI-H1648	MoDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXPJR\|UxRTRwMUOgcm0>	NEjrUFhUSU6JRWK=
OMC-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVm1SJFiUUN3ME20MlE5KG6P	MkCxV2FPT0WU
LB647-SCLC	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml\PTWM2OD12LkKyJI5O	MWHTRW5ITVJ?
TE-12	M1LS[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUjjNVI3UUN3ME20MlI2KG6P	NFLmcmZUSU6JRWK=
NOMO-1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVnuN2lLUUN3ME20MlM{KG6P	M3\zRnNCVkeHUh?=
Raji	MoXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIHvSYNKSzVyPUSuOFYhdk1?	NHHhXlFUSU6JRWK=
NALM-6	NWi3VG4{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFO0PJBKSzVyPUSuOFkhdk1?	MnzQV2FPT0WU
HL-60	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3\GNmlEPTB;ND62O{BvVQ>?	NHT1RnVUSU6JRWK=
IST-SL1	M13WeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3u0b2lEPTB;ND62PEBvVQ>?	MXrTRW5ITVJ?
MHH-PREB-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGnnUZRKSzVyPUSuPFYhdk1?	MYTTRW5ITVJ?
MHH-NB-11	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF7wd41KSzVyPUSuPVEhdk1?	MYPTRW5ITVJ?
JiyoyeP-2003	NVX0bXhIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFrHfoJKSzVyPUWgcm0>	NYPZdGxjW0GQR1XS
SBC-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2jhW2lEPTB;NT6wNUBvVQ>?	MWrTRW5ITVJ?
CHP-126	MmraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4HGemlEPTB;NT6wOkBvVQ>?	NYTETmVQW0GQR1XS
LU-139	MoewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFPPdnFKSzVyPUWuNVMhdk1?	NHPES3FUSU6JRWK=
NCI-SNU-5	MmDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHOyTodKSzVyPUWuNVchdk1?	MoPCV2FPT0WU
SW962	NXK0OJkyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIrwSVlKSzVyPUWuNlEhdk1?	M1zhR3NCVkeHUh?=
EW-1	Mn;FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NECyV3FKSzVyPUWuN\|Ehdk1?	NIrVOGlUSU6JRWK=
NCI-H1417	NEL2dY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3nme2lEPTB;NT61NUBvVQ>?	M2e4fHNCVkeHUh?=
LU-65	NHzSSnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVzYbHNGUUN3ME21Mlg1KG6P	NIjPV5lUSU6JRWK=
D-502MG	NGLlToxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVG1clE2UUN3ME22MlM4KG6P	MkXnV2FPT0WU
BC-3	MnniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYnCW5RNUUN3ME22MlYyKG6P	NWi2eJdiW0GQR1XS
GDM-1	NGC0clBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTZwN{egcm0>	NVrOeXZRW0GQR1XS
NCI-H2196	M1zyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUnYbpN6UUN3ME22Mlghdk1?	MVLTRW5ITVJ?
NB1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlHQTWM2OD14Lki4JI5O	M4PGO3NCVkeHUh?=
NCI-H345	MlPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWDJR\|UxRTdwMjDuUS=>	NEPRRYJUSU6JRWK=
SU-DHL-1	NVv6NHpET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml3UTWM2OD15LkK0JI5O	NWLRdHVuW0GQR1XS
JVM-2	M1i1c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn\TTWM2OD15LkK4JI5O	MkjDV2FPT0WU
LU-134-A	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFnsUlVKSzVyPUeuN\|khdk1?	NVf4e3RwW0GQR1XS
NCI-H1694	NXnQNHNtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUT4cnFPUUN3ME23MlU5KG6P	MYPTRW5ITVJ?
NCI-SNU-16	NWX3U4FTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTdwNkWgcm0>	MnfUV2FPT0WU
L-363	M2[1UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2LnbWlEPTB;Nz63JI5O	NILMPGlUSU6JRWK=
KG-1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MonDTWM2OD15Lkm0JI5O	MlX0V2FPT0WU
MN-60	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1TLSGlEPTB;OD6xOEBvVQ>?	NUf3PXQzW0GQR1XS
NB6	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NI\tOplKSzVyPUiuOFghdk1?	NXLTeFhWW0GQR1XS
MLMA	Ml\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXjJR\|UxRThwOEWgcm0>	NH31ZWVUSU6JRWK=
ATN-1	M3iySGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXjzW5I{UUN3ME24Mlg6KG6P	MkLnV2FPT0WU
SK-NEP-1	M3yxUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mnf6TWM2OD17LkCxJI5O	M2PHOHNCVkeHUh?=
DMS-114	MnSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXjJR\|UxRTlwNkKgcm0>	NVOxeG85W0GQR1XS
CTB-1	NYDxSmE{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXO2SoRJUUN3ME25MlY4KG6P	NIHLRY5USU6JRWK=
NCI-H2081	NXjM[nZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnTRTWM2OD1zMD6wPUBvVQ>?	NUjkZnZTW0GQR1XS
ES5	NFHFSFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYrJR\|UxRTFyLkO4JI5O	MXPTRW5ITVJ?
HCC1599	MmrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVvJR\|UxRTFzLkmxJI5O	M1;ycXNCVkeHUh?=
NCI-H23	NF3I[m5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm[0TWM2OD1zMj6xNkBvVQ>?	NWOzWFFWW0GQR1XS
NCI-H1581	NWO5NYZDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlOzTWM2OD1zMj6yPEBvVQ>?	MX3TRW5ITVJ?
JVM-3	NWrNbnZRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mm\tTWM2OD1zMj65PUBvVQ>?	M2fhSnNCVkeHUh?=
NCI-SNU-1	NVi2[4MyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWnCZWZJUUN3ME2xN{4yQSCwTR?=	MYPTRW5ITVJ?
NB7	NYLEe4NRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MofETWM2OD1zNT65NkBvVQ>?	M1fsXHNCVkeHUh?=
JAR	NUjiN\|VuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3XIZ2lEPTB;MU[uNVMhdk1?	NVzucYVHW0GQR1XS
TGW	M2r5fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWHJR\|UxRTF4LkS4JI5O	M4X2PXNCVkeHUh?=
U-87-MG	NYryeXhzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUfhPGVHUUN3ME2xOk44PiCwTR?=	NXvvSYhqW0GQR1XS
NCI-H1436	NVXQRpp{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGDod2RKSzVyPUG3MlAyKG6P	NWXkXFRFW0GQR1XS
GOTO	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MU\JR\|UxRTF5LkC2JI5O	NYfp[phQW0GQR1XS
COLO-800	MmT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEHpc5hKSzVyPUG3MlY1KG6P	MUHTRW5ITVJ?
MFM-223	NYrXR4F[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV7me5pHUUN3ME2xO{46OSCwTR?=	MX7TRW5ITVJ?
EW-18	MnjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVPJR\|UxRTF5Lkm2JI5O	NIrMRlVUSU6JRWK=
NB14	M4rVVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX;xUZduUUN3ME2xO{46QCCwTR?=	Mn[yV2FPT0WU
EB2	M1z5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3LMdmlEPTB;MUiuNFghdk1?	M3vne3NCVkeHUh?=
EoL-1-	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M33JemlEPTB;MUiuN\|Ehdk1?	MYLTRW5ITVJ?
NCCIT	M4WzXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUPJR\|UxRTF6LkO2JI5O	NWD0dWxiW0GQR1XS
DG-75	NFrx[XFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWGxVZFSUUN3ME2xPE43OSCwTR?=	NHvo[GZUSU6JRWK=
HCC2218	M3\uU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3jaXWlEPTB;MUmuOUBvVQ>?	MlnlV2FPT0WU
TE-6	NVexOYJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4T0[GlEPTB;MkCuNFghdk1?	NH25SJlUSU6JRWK=
SF539	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHrGOmlKSzVyPUKwMlY4KG6P	Mn3CV2FPT0WU
NCI-H446	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWnJR\|UxRTJzLkG4JI5O	Mln0V2FPT0WU
IST-MES1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGewS3ZKSzVyPUKyMlc4KG6P	NWTIe25jW0GQR1XS
NCI-H82	Mn36S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmPsTWM2OD1{Mz6wNkBvVQ>?	MmjmV2FPT0WU
HCC2157	MlLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVLJR\|UxRTJ\|LkGzJI5O	MV7TRW5ITVJ?
EW-12	MonMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYHOUm9oUUN3ME2yN{4yPyCwTR?=	Mn3wV2FPT0WU
SIMA	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF;xUpdKSzVyPUKzMlM5KG6P	NHu0SlRUSU6JRWK=
DOHH-2	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUnJR\|UxRTJ\|LkS1JI5O	NVLUbXhDW0GQR1XS
IM-9	NIq2O25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVzUV\|BqUUN3ME2yN{42PCCwTR?=	M{PDXHNCVkeHUh?=
EC-GI-10	M33hU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUT4[3o5UUN3ME2yOE4zOyCwTR?=	NI\BV4JUSU6JRWK=
HDLM-2	MmnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHnVcHJKSzVyPUK0MlU1KG6P	MlvJV2FPT0WU
LS-1034	MlPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M33WWWlEPTB;MkWuO\|Uhdk1?	M1njfHNCVkeHUh?=
REH	NFjQWZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEn1ZmdKSzVyPUK2MlQyKG6P	M2ja[3NCVkeHUh?=
LU-165	MnLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2HJUGlEPTB;Mk[uO\|Ihdk1?	NGfzbINUSU6JRWK=
NH-12	NVfwU\|czT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFTtemxKSzVyPUK3MlY4KG6P	MUXTRW5ITVJ?
WSU-NHL	Ml7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4LqfGlEPTB;MkiuN\|khdk1?	Mn31V2FPT0WU
ECC4	Moj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkfVTWM2OD1{OD63PUBvVQ>?	NUXqTGljW0GQR1XS
OCI-AML2	M4rF[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYLJR\|UxRTJ7Lk[5JI5O	NInkbGxUSU6JRWK=
EW-3	MmWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUTJR\|UxRTNyLkW5JI5O	NHrSUpFUSU6JRWK=
NCI-H526	NW\5RYRDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2O4bWlEPTB;M{KuOVQhdk1?	NXXINnFNW0GQR1XS
NCI-H719	NWf5e5JTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFfwWpdKSzVyPUO0MlMyKG6P	NHrIeG5USU6JRWK=
KARPAS-422	M3[0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mm[4TWM2OD1\|NT6wOEBvVQ>?	NYK2UYx6W0GQR1XS
SK-MEL-1	NIXyfJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MY\JR\|UxRTN3LkG3JI5O	MXTTRW5ITVJ?
ES3	NH76[odIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml;5TWM2OD1\|NT6xPUBvVQ>?	NITJc3NUSU6JRWK=
UACC-812	MofuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkLNTWM2OD1\|NT60OEBvVQ>?	MlzsV2FPT0WU
C8166	NU\NUW46T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2\XV2lEPTB;M{WuO{BvVQ>?	Mn[yV2FPT0WU
MDA-MB-134-VI	NXTMc5RrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIjvNlFKSzVyPUO1Mlg4KG6P	NFfuW3VUSU6JRWK=
D-283MED	M{DmR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWXJR\|UxRTN5Lke5JI5O	M2DBfnNCVkeHUh?=
SHP-77	NXq2UZFGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4\5UGlEPTB;M{iuNFMhdk1?	NGXISGNUSU6JRWK=
NCI-H2227	NIqzZm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXvJR\|UxRTRyLkS5JI5O	M17hZXNCVkeHUh?=
SKM-1	MoXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVLjPYs6UUN3ME20Nk43OyCwTR?=	NFP2RotUSU6JRWK=
L-428	NYHYR4k3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MULJR\|UxRTR\|Lki2JI5O	NWroVG1QW0GQR1XS
RPMI-6666	M3z2WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2HmSmlEPTB;NEWuPFkhdk1?	MlHIV2FPT0WU
NCI-H716	M1;TNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUTJR\|UxRTR6LkixJI5O	MYLTRW5ITVJ?
DMS-79	NWK0cYVCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYiyOXl2UUN3ME21NE44OSCwTR?=	MVLTRW5ITVJ?
RS4-11	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV3JR\|UxRTVyLki4JI5O	MoXqV2FPT0WU
NCI-H720	NFXwd5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFf6[\|RKSzVyPUWxMlEyKG6P	MXzTRW5ITVJ?
MC-CAR	M3T6SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUfJR\|UxRTVzLkWyJI5O	MkTJV2FPT0WU
TALL-1	NUjU[4xxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkHvTWM2OD13Mz65NUBvVQ>?	NXLSVlJzW0GQR1XS
NCI-N87	M3PDeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHnsUFNKSzVyPUW0MlE5KG6P	MmjEV2FPT0WU
P30-OHK	NV3B[GVsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkXkTWM2OD13ND62NUBvVQ>?	MU\TRW5ITVJ?
LP-1	M{LKRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NU\BN4hXUUN3ME22NU4zQCCwTR?=	NEmxeIVUSU6JRWK=
YT	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVHY[Y5JUUN3ME22NU45KG6P	M1fpcHNCVkeHUh?=
MRK-nu-1	MnXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH\EVXRKSzVyPU[xMlgzKG6P	M{PZSXNCVkeHUh?=
BT-474	MnixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX7JR\|UxRTZ3IH7N	M2C1Z3NCVkeHUh?=
NCI-H322M	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFi5Z4RKSzVyPU[2MlEyKG6P	MXfTRW5ITVJ?
NCI-H128	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoO5TWM2OD15ND63O{BvVQ>?	MW\TRW5ITVJ?
KMS-12-PE	NXjNV3VqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHzFXnBKSzVyPUe2MlI1KG6P	MmX4V2FPT0WU
KP-N-YS	M1m4OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml3yTWM2OD15Nj63OEBvVQ>?	MorlV2FPT0WU
ALL-PO	M3\rd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGPj[lZKSzVyPUe3MlY3KG6P	MVPTRW5ITVJ?
EW-13	NVX6eIxTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{PhfGlEPTB;N{euO\|Yhdk1?	Mnz3V2FPT0WU
EW-11	NUfKcXA6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHXjZ49KSzVyPUe4MlUzKG6P	MoDuV2FPT0WU
SK-N-FI	MkfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NILDR4JKSzVyPUiwMlIhdk1?	MYjTRW5ITVJ?
CAL-148	NF;FSXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYXJR\|UxRThzLki0JI5O	NXL1T3JzW0GQR1XS
RL	NWHmNZlsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4e4WGlEPTB;OE[uNFkhdk1?	NWLVRmx5W0GQR1XS
AM-38	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3r2NmlEPTB;OEiuNFghdk1?	NXfpdYo5W0GQR1XS
RH-1	NFWwW2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXzDTI5zUUN3ME25PU45PSCwTR?=	NUfuT5lnW0GQR1XS
NCI-H1770	NXPGOlNFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NInITJFKSzVyPUGwNk41QSCwTR?=	MXTTRW5ITVJ?
SIG-M5	M{nJ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEHpZ2FKSzVyPUGwOU4xPiCwTR?=	MkDtV2FPT0WU
GR-ST	NFPpR4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEP6cmhKSzVyPUGxN{4{PCCwTR?=	M2rWVXNCVkeHUh?=
ST486	Ml;oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1fHdWlEPTB;MUG0MlA3KG6P	NXuw[pRYW0GQR1XS
NCI-H1650	Mo\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWfJR\|UxRTFzNT6yPUBvVQ>?	M3XXTnNCVkeHUh?=
MHH-CALL-2	NWD6PFM5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVnod2cyUUN3ME2xNVUvPyCwTR?=	Mn;6V2FPT0WU
BV-173	MkjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{K2dGlEPTB;MUKyMlcyKG6P	NFS5eXBUSU6JRWK=
MC116	NGHaNVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIXjOJZKSzVyPUG0PE45PSCwTR?=	NHjPRWFUSU6JRWK=
NCI-H524	NH\4[41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVjJR\|UxRTF3OT6xJI5O	M1HOdHNCVkeHUh?=
SCLC-21H	NVrLUHFnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1\XPGlEPTB;MUW5MlQyKG6P	NXPqXZJSW0GQR1XS
NCI-H1304	NEjIe\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX3JR\|UxRTF4OT6yNUBvVQ>?	M2fUTHNCVkeHUh?=
NCI-H510A	MnHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlvCTWM2OD1zOEWuN\|chdk1?	NIS2N3hUSU6JRWK=
NCI-H209	M1:4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1u5[WlEPTB;MUm2MlUzKG6P	NWXadWppW0GQR1XS
KM-H2	MmPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUTJR\|UxRTF7Nz6wOUBvVQ>?	M3fQVHNCVkeHUh?=
NCI-H1395	NVzWUG86T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEHoWJBKSzVyPUKxNE4yOyCwTR?=	NE\GPGRUSU6JRWK=
NCI-H1155	NH7GbolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHnzU\|BKSzVyPUKzNE4{OiCwTR?=	MXvTRW5ITVJ?
COR-L279	MnHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWXadmdSUUN3ME2yOVIvOTdibl2=	NGmyTVhUSU6JRWK=
NCI-H1299	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4q2PGlEPTB;Mk[xMlcyKG6P	M2T5ZnNCVkeHUh?=
EW-22	NITR[ZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHPRT3NKSzVyPUK2N{44PSCwTR?=	MoHBV2FPT0WU
SK-MEL-2	NXLiWG5qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnOwTWM2OD1{OEGuPUBvVQ>?	NFL0XGJUSU6JRWK=
KASUMI-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYnNdW9lUUN3ME2yPFMvODVibl2=	NVe1XGZvW0GQR1XS
NCI-H187	M2jEOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWjJR\|UxRTJ6Nz6wPEBvVQ>?	NV3HVIRGW0GQR1XS
NCI-H2171	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mk\tTWM2OD1{OEiuPVIhdk1?	MmPoV2FPT0WU
LNCaP-Clone-FGC	NWL4b3V2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGjJe4VKSzVyPUK5OU4zPiCwTR?=	NGnp[4VUSU6JRWK=
NCI-H1522	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXzCc4ppUUN3ME2zNFcvODVibl2=	MkD2V2FPT0WU
SCH	NVXTe\|dST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVjmWm5GUUN3ME2zNlIvOjJibl2=	MkXCV2FPT0WU
THP-1	MkS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYnPcYxkUUN3ME2zNlIvPiCwTR?=	MX3TRW5ITVJ?
SNU-C1	MoXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXHJR\|UxRTN4Mj6wPUBvVQ>?	MVXTRW5ITVJ?
CA46	NFSzSnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYnNPIx4UUN3ME2zO\|MvPjNibl2=	NWHZPIJiW0GQR1XS
NCI-H1963	NEPJcHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{jxRWlEPTB;M{i2MlE6KG6P	MnfDV2FPT0WU
DEL	NVrsfmVLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mk\2TWM2OD1\|OUGuNlchdk1?	M1jsVXNCVkeHUh?=
TUR	NXLkXm8{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFLqO4dKSzVyPUO5Ok43OSCwTR?=	MXnTRW5ITVJ?
NCI-H226	MoC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIDIZppKSzVyPUSwN{4zOyCwTR?=	MVzTRW5ITVJ?
COLO-668	NH;4boNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlfsTWM2OD12MEOuOVchdk1?	NF\nTnNUSU6JRWK=
CPC-N	NF7aV5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M13vdmlEPTB;NECzMlc4KG6P	NIPIdoRUSU6JRWK=
NCI-H889	NUTnVI1yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn7MTWM2OD12NkGuPVIhdk1?	MlLqV2FPT0WU
J-RT3-T3-5	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX:0fJIxUUN3ME21N\|IvPTdibl2=	MmroV2FPT0WU
MSTO-211H	MljoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWrzUWpNUUN3ME21O\|QvOjZibl2=	NVjOUIFPW0GQR1XS
SCC-15	M4\pWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXXJR\|UxRTZ4Nz60O{BvVQ>?	NFHTTVBUSU6JRWK=
SUP-T1	M1vuS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEPxZ2tKSzVyPU[4Ok4xPCCwTR?=	NV;hSFJDW0GQR1XS
DMS-153	MoL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIjWZnVKSzVyPUe0Ok45OyCwTR?=	Mn3aV2FPT0WU
MS-1	NUftSph{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3zoe2lEPTB;N{W5MlQzKG6P	M1vYWXNCVkeHUh?=
TC-YIK	NWXCUHZDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mm\zTWM2OD15OEGuNFEhdk1?	NXPsRoNzW0GQR1XS
RPMI-8866	NV3jOXc{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MU\JR\|UxRTFyME[uNlgh\|ryP	Ml[0V2FPT0WU
KY821	MlHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYfZUIZTUUN3ME2xNFM3NjB2IN88US=>	MUfTRW5ITVJ?
P31-FUJ	MkDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2fYTWlEPTB;MUGxNk44PSEQvF2=	NYTLZlh{W0GQR1XS
COLO-824	MkDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M17kUGlEPTB;MUK2NU44QCEQvF2=	MYfTRW5ITVJ?
U-698-M	NYPuU3k2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4PPR2lEPTB;MkK2Nk4yPSEQvF2=	M1W5eXNCVkeHUh?=
TE-441-T	NITV[HFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NULxcFlTUUN3ME2yOVIyNjdizszN	MXzTRW5ITVJ?
IMR-5	NVy5enpST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIeyTnZKSzVyPUO0NFkvPjJizszN	NVXwXJh2W0GQR1XS
NCI-H1838	NX3lUYpLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUTLfXc1UUN3ME20NVg3NjN{IN88US=>	MXzTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	phospho-PERK / ATF-4; PubMed: 15509775 Mol Cell Biol UMSCC-23 cells were treated with PS-341 for the indicated time periods and concentrations. Whole-cell extracts were prepared, and 50-μg aliquots of proteins were probed with polyclonal antibodies against phospho-PERK, ATF-4. For loading control, the membranes were stripped and reprobed with monoclonal antibodies against α-tubulin. GRP-78 / GADD-34; PubMed: 15509775 Mol Cell Biol UMSCC-23 cells were treated with PS-341 for the indicated time periods and concentrations. Whole-cell extracts were prepared, and 50-μg aliquots of proteins were probed with polyclonal antibodies against GRP-78, and GADD-34. For loading control, the membranes were stripped and reprobed with monoclonal antibodies against α-tubulin. pro-caspase-12 / pro-caspase-3; PubMed: 15509775 Mol Cell Biol MEFs were treated with PS-341 for the indicated time periods, and the whole-cell extracts were prepared. Fifty-microgram aliquots of proteins were probed with polyclonal antibodies against caspase 12 and caspase 3. For loading control, the membrane was stripped and reprobed with monoclonal antibodies against α-tubulin. pro-caspase-9; PubMed: 15509775 Mol Cell Biol UMSCC-23 cells were pretreated with or without Tiron for 30 min and then treated with PS-341 for the indicated time periods. The whole-cell proteins were probed with polyclonal antibodies against caspases 9 and 3. For loading control, the membrane was stripped and reprobed with monoclonal antibodies against α-tubulin. p-IκBα / IκBα; PubMed: 20335171 J Biol Chem PS-341 induces IκBα degradation in human lung cancer cells. The given cells lines were treated with the indicated concentrations of PS-341 for 8 h (C). After treatment, the cells were then subjected to preparation of whole-cell protein lysates and subsequent Western blot analysis. COX-2 / cIAP2; PubMed: 24085292 J Biol Chem NCI-H157 cells were incubated with PS-341 (50 nM) or MG132 (20 μM) for the indicated times. Total cellular extracts were subjected to Western blot analysis for COX-2, cIAP2 and actin.	15509775 20335171 24085292
Immunofluorescence	Vimentin; PubMed: 19010849 Clin Cancer Res ES-2 ovarian cancer cells were incubated with 5nM PS-341, 10 μM NK84 or the combination of both for 24 hours before fixation and immuno-fluorescent staining of DNA (blue), ubiquitin (green) and vimentin (red) and imaging (X60 objective). Ubiquitin; PubMed: 19010849 Clin Cancer Res IOSE-29 cells were incubated with 20nM PS-341 for 24 hours before fixation and immuno-fluorescent staining of DNA (blue), ubiquitin (green) and vimentin (red) and imaging (X60 objective).	19010849
Growth inhibition assay	Cell viability ; PubMed: 20571067 Mol Cancer Ther A, TSA enhanced the cell death induced by PS-341 in UMSCC1 cells. Cell viability was determined by the trypan blue exclusion assay. The assays were performed with triplicate samples, and the results are representative of three independent experiments (P < 0.01). Error bars depict standard deviation. B, C and D, TSA enhanced PS-341-induced cell death in UMSCC23 (B), UMSCC9 (C), and FaDu (D). P < 0.01.	20571067
ELISA	IL-8; PubMed: 24085292 J Biol Chem NCI-H157 cells were treated with PS-341 (10–100 nm) or TNF-α (10 ng/ml) as a positive control for 24 h. IL-8 concentrations in media were determined by ELISA. Data represent the mean ± S.D. of triplicates. **, p < 0.05 versus control cells. Results are representative of three separate experiments.	24085292

In vivo

The anticancer effects of bortezomib as a single agent have been demonstrated in xenograft models of multiple myeloma, adult T-cell leukemia, lung, breast, prostate, pancreatic, head and neck, and colon cancer, and in melanoma. ^[2] Oral bortezomib 1.0 mg/ kg daily for 18 days causes tumor growth delays, as well as a decrease in the number of metastases in the Lewis lung cancer model. Bortezomib at a single dose of up to 5 mg/kg significantly decreased the surviving fraction of breast tumor cells. Bortezomib 1.0 mg/kg administrated weekly for 4 weeks reduces tumor growth by 60% in murine xenograft models of prostate cancer. 1.0 mg/kg Bortezomib administration for 4 weeks results in a 72% or 84% reduction in pancreatic cancer murine xenografts growth, as well as an increase in tumor cell apoptosis. 1.0 mg/kg Bortezomib treatment results in significant inhibition of human plasmacytoma xenograft growth, increase in tumor cells apoptosis and overall survival, and a decrease in tumor angiogenesis. ^[3]

Protocol

Kinase Assay: ^[4]	+ Expand Kinetic Methods: In a typical kinetic run, 2.00 mL of assay buffer (20 mM HEPES, 0.5 mM EDTA, 0.035% SDS, pH 7.8) and Suc-Leu-Leu-Val-Tyr-AMC in DMSO are added to a 3 mL fluorescence cuvette, and the cuvette is placed in the jacketed cell holder of a fluorescence spectrophotometer. Reaction temperature is maintained at 37℃ by a circulating water bath. After the reaction solution has reached thermal equilibrium (5 minutes), 1 μL−10 μL of the stock enzyme solution is added to the cuvette. Reaction progress is monitored by the increase in fluorescence emission at 440 nm (λ_ex= 380 nm) that accompanies cleavage of AMC from peptide-AMC substrates.
Cell Research: ^[5]	+ Expand Cell lines: Human multiple myeloma cells line U266 Concentrations: ~10 μM Incubation Time: 2 days Method: The inhibitory effect of Bortezomib on cell growth is assessed by measuring MTT dye absorbance of the cells. Cells from 48-hour cultures are pulsed with 10 μL of 5 mg/mL MTT to each well for the last 4 hour of 48-hour cultures, followed by 100 μL of isopropanol containing 0.04 N HCl. Absorbance is measured at 570 nm using a spectrophotometer. (Only for Reference)
Animal Research: ^[3]	+ Expand Animal Models: Human plasmacytoma xenografts RPMI 8226 Formulation: Saline Dosages: 1 mg/kg Administration: i.v. twice weekly for 4 weeks, then once weekly (Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	DMSO	76 mg/mL (197.79 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Bortezomib (PS-341) SDF

Molecular Weight	384.24
Formula	C₁₉H₂₅BN₄O₄
CAS No.	179324-69-7
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	LDP-341, MLM341

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03829020	Not yet recruiting	Recurrent Plasma Cell Myeloma\|Refractory Plasma Cell Myeloma	Mayo Clinic\|National Cancer Institute (NCI)	March 1 2019	Phase 1
NCT03617484	Recruiting	Mantle Cell Lymphoma	University of Michigan Rogel Cancer Center	March 2019	Phase 2
NCT03617484	Recruiting	Mantle Cell Lymphoma	University of Michigan Rogel Cancer Center	March 2019	Phase 2
NCT03878524	Not yet recruiting	Breast Cancer\|Prostate Cancer\|Pancreatic Cancer\|Acute Myelogenous Leukemia	OHSU Knight Cancer Institute\|Oregon Health and Science University\|Prospect Creek Foundation	March 14 2019	Phase 1
NCT03829020	Not yet recruiting	Recurrent Plasma Cell Myeloma\|Refractory Plasma Cell Myeloma	Mayo Clinic\|National Cancer Institute (NCI)	March 1 2019	Phase 1
NCT03878524	Not yet recruiting	Breast Cancer\|Prostate Cancer\|Pancreatic Cancer\|Acute Myelogenous Leukemia	OHSU Knight Cancer Institute\|Oregon Health and Science University\|Prospect Creek Foundation	March 14 2019	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
On your website, it is mentioned that Bortezomib should be prepared at a concentration of 5 mg/ml in 2% DMSO/30% PEG300/ddH2O for in vivo use. But on the product sheet we received with the compound, it is mentioned: 5mg/ml in 0.5% methylcellulose, 0.2% tween 80. So which is the correct preparation buffer?
Answer:
S1013 Bortezomib in 2% DMSO+30% PEG 300+ddH2O at 5 mg/ml is a clear solution, and it in 0.5% methylcellulose+0.2% Tween 80 is a suspension. Please choose the suitable vehicle according to your administration route. When you prepare the clear solution, please dissolve Bortezomib in DMSO first, make sure it dissolves well, warm it up to 45 degree and/or sonicate if necessary, then add PEG, mix well, and finally add water.

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

Pan Proteasome Inhibitor

Ixazomib (MLN2238) : β5 site, IC50=3.4 nM; β1 site, IC50=31 nM; β2 site, IC50=3500 nM.
FDA-approved Proteasome Inhibitor

Carfilzomib (PR-171) : Approved by FDA for multiple myeloma.
Newest Proteasome Inhibitor

Oprozomib (ONX 0912) : Orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM.

Related Proteasome Products3

VR23 ^New

VR23 is a potent proteasome inhibitor with IC50 of 1 nM, 50-100 nM, and 3 μM for trypsin-like proteasomes, chymotrypsin-like proteasomes, and caspase-like proteasomes, respectively.
Calpeptin ^New

Calpeptin is a potent, cell-permeable calpain inhibitor with ID50 of 52 nM, 34 nM, 138 nM, and 40 nM for Calpain I (porcine erythrocytes), Calpain II (porcine kidney), Papainb, and Calpain I (human platelets), respectively.
Marimastat (BB-2516) ^New

Marimastat (BB-2516) is a broad spectrum matrix metalloprotease (MMP) inhibitor for MMP-9, MMP-1, MMP-2, MMP-14 and MMP-7 with IC50 of 3 nM, 5 nM, 6 nM, 9 nM and 13 nM, respectively. Phase 3.
MG-132

MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 and 1.2 μM for the inhibition of proteasome and calpain, respectively.
Carfilzomib (PR-171)

Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities.
Ixazomib (MLN2238)

MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and K_i of 3.4 nM and 0.93 nM in cell-free assays, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31 and 3500 nM. Phase 3.

Features:A first-in-class proteasome inhibitor that has improved pharmacokinetics (PK), pharmacodynamics(PD), and antitumor activity in preclinical studies.
Ixazomib Citrate (MLN9708)

Ixazomib Citrate (MLN9708) immediately hydrolyzed to MLN2238, the biologically active form, on exposure to aqueous solutions or plasma. MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50/K_i of 3.4 nM/0.93 nM in cell-free assays, less potent to β1 and little activity to β2. Phase 3.

Features:The 1st oral proteasome inhibitor in early stage clinical trials for Multiple Myeloma.
Celastrol

Celastrol is a potent proteasome inhibitor for the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM.

Features:A potent antioxidant and anti-inflammatory drug.
Oprozomib (ONX 0912)

Oprozomib (ONX 0912) is an orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM. Phase 1/2.

Choose Your Country or Region

By Signaling Pathways

By product type

Bortezomib (PS-341)

Cited by 190 Publications

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Bortezomib (PS-341) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

Related Proteasome Products3

Choose Your Country or Region

By Signaling Pathways

By product type

Bortezomib (PS-341)

Cited by 190 Publications

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Bortezomib (PS-341) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

Related Proteasome Products3

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)